Diagnosing squamous cell carcinoma of the lung involves several specialized tests and imaging procedures that help doctors identify this specific type of lung cancer and determine its extent. Early and accurate diagnosis is crucial for planning the most effective treatment approach and improving outcomes for patients with this smoking-related lung cancer.

Introduction: Who Should Consider Diagnostic Testing

People who should undergo diagnostic testing for squamous cell carcinoma of the lung include those experiencing symptoms such as persistent cough, chest pain, shortness of breath, coughing up blood, hoarseness, wheezing, or unexplained weight loss. These symptoms may indicate the presence of lung cancer, though many people do not experience symptoms in the early stages of the disease.^[2]

Individuals with a history of smoking are at particularly high risk for developing squamous cell carcinoma of the lung, as smoking is the principal cause of this cancer type. Approximately 80% of lung cancer cases in men and 90% in women are associated with smoking, and squamous cell carcinoma is more strongly linked to smoking than any other type of non-small cell lung cancer.^[2] Even people who have quit smoking should remain vigilant about symptoms and discuss screening options with their healthcare provider.

Other risk factors that should prompt consideration of diagnostic testing include advancing age, family history of lung cancer, exposure to secondhand smoke, and occupational exposure to harmful substances such as asbestos, uranium, arsenic, or radon gas. People exposed to asbestos on the job—including miners, construction workers, shipyard workers, and some auto mechanics—have a higher-than-normal risk of lung cancer and should be especially attentive to respiratory symptoms.^[5]

Interestingly, squamous cell carcinoma tumors often start in the central part of the lungs rather than the outer edges. Because of this location, these tumors may cause symptoms such as coughing up blood at an earlier stage compared to other types of lung cancer like adenocarcinoma (a cancer that begins in mucus-producing cells). This earlier symptom presentation can sometimes lead to earlier diagnosis, which is why it’s important to seek medical attention promptly when respiratory symptoms appear.^[5]

Classic Diagnostic Methods

The diagnostic process for squamous cell carcinoma of the lung begins with a thorough clinical examination. Your doctor will take a complete medical history, asking about your symptoms, smoking habits, occupational exposures, and family history of cancer. This conversation helps identify risk factors and determines which tests are most appropriate for your situation.^[2]

Imaging Studies

After the initial clinical assessment, computed tomography (CT) imaging is frequently the first test used to evaluate suspected squamous cell carcinoma, provided the tumor is large enough to be detected on the scan. A CT scan uses X-rays and computer technology to create detailed, three-dimensional images of the lungs and surrounding structures. This imaging technique is much more detailed than a standard chest X-ray and can reveal the size, shape, and location of tumors.^[2]

The CT scan helps doctors see whether there is a mass in the central airways—the left or right bronchus (the main breathing tubes leading from the windpipe to each lung)—where squamous cell carcinomas typically develop. The scan can also show whether the cancer has spread to nearby lymph nodes or other structures in the chest.^[2]

In addition to CT imaging, other imaging modalities may be used as part of the diagnostic workup. These can include chest X-rays as an initial screening tool, though they are less detailed than CT scans. For more complex cases, doctors may order additional imaging such as magnetic resonance imaging (MRI), positron emission tomography (PET) scans, or bone scans to determine if the cancer has spread to other parts of the body, including the brain, bones, liver, or adrenal glands.^[5]

Tissue Sampling and Biopsy

While imaging tests can suggest the presence of lung cancer, a definitive diagnosis requires obtaining tissue samples for examination under a microscope. This process is called a biopsy. If lung cancer is suspected based on imaging results, you will need to have a biopsy to confirm the diagnosis and identify the specific type of cancer.^[7]

Several different biopsy techniques may be used depending on the location and size of the tumor. Bronchoscopy is a common procedure in which a thin, flexible tube with a light and camera is inserted through the nose or mouth, down the throat, and into the airways. This allows the doctor to visually examine the inside of the bronchi and collect tissue samples from suspicious areas. Because squamous cell carcinomas often occur in the central airways, bronchoscopy is particularly useful for this type of lung cancer.

Other biopsy methods include needle biopsy, in which a thin needle is inserted through the chest wall to collect tissue samples from the lung, and thoracentesis, which involves removing fluid from around the lungs if fluid buildup is present. In some cases, more invasive surgical procedures such as thoracoscopy (examination of the chest cavity through small incisions) or mediastinoscopy (examination of the area between the lungs) may be necessary to obtain adequate tissue samples or assess lymph node involvement.

Another diagnostic technique is sputum cytology, which examines mucus coughed up from the lungs for the presence of cancer cells. While less invasive than other methods, sputum cytology may not always provide enough information for a definitive diagnosis.

Histological and Immunohistochemistry Analysis

Once tissue samples are obtained, they undergo detailed laboratory analysis. Histological analysis involves examining the cells under a microscope to identify their type and characteristics. Squamous cell carcinoma is named for the thin, flat squamous cells that line the airways. When these cells become abnormal and begin to multiply uncontrollably, they form cancer.^[4]

The cancer cells in squamous cell carcinoma look different under the microscope compared to other types of lung cancer, such as adenocarcinoma or small cell lung cancer. This microscopic appearance is crucial for accurate diagnosis because different types of lung cancer are treated differently, and the prognosis can vary significantly between types.^[5]

Immunohistochemistry is an additional laboratory technique that may be performed on tissue specimens. This test uses antibodies to identify specific proteins or markers on the surface of cancer cells, helping to further characterize the tumor and confirm the diagnosis. These evaluations are typically performed to distinguish squamous cell carcinoma from other types of non-small cell lung cancer and to guide treatment decisions.^[2]

Staging the Disease

After confirming the diagnosis of squamous cell carcinoma, additional tests are done to determine the stage of the cancer—that is, how far it has spread within the chest or to other parts of the body. Staging is essential because it guides treatment decisions and helps predict outcomes.^[7]

Squamous cell carcinoma of the lung follows the same staging system as other non-small cell lung cancers. Stage 0 means the cancer is found only in the top lining of the lung and has not spread outside the lung. Stage I indicates the cancer has not spread to the lymph nodes or other parts of the body, with substages based on tumor size. Stage II means the cancer is larger and has begun to spread to nearby lymph nodes or tissues, but not to distant organs. Stage III indicates more extensive spread within the chest, possibly making surgical removal difficult. Stage IV means the cancer has spread to other areas of the body outside the lungs, such as the liver, bones, or brain.^[4]

The staging process may involve additional imaging tests, lymph node biopsies, and other procedures to get a complete picture of the cancer’s extent. Understanding the stage is critical because treatment approaches differ significantly between early-stage cancers that may be treated with surgery and advanced-stage cancers that may require chemotherapy, radiation, or other systemic treatments.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for cancer. For patients with squamous cell carcinoma of the lung, participating in a clinical trial may provide access to promising new therapies that are not yet widely available. However, enrollment in clinical trials requires meeting specific eligibility criteria, which are determined through various diagnostic tests.^[2]

The standard diagnostic tests used to qualify patients for clinical trials are similar to those used for general diagnosis and staging, but they may be more extensive or require more recent results. Clinical trials typically require confirmation of the cancer diagnosis through biopsy and histological examination. The tissue samples must clearly show squamous cell carcinoma rather than another type of lung cancer, as many trials are designed specifically for certain cancer subtypes.

Staging information is critical for clinical trial eligibility. Most trials specify which stages of cancer they are studying—for example, some may focus on early-stage cancers that have not spread beyond the lung, while others may focus on advanced-stage cancers that have spread to distant organs. Complete staging workup including CT scans, PET scans, and sometimes brain MRI may be required to accurately determine eligibility.

Many clinical trials also require recent imaging studies, often performed within a specific time frame before enrollment, such as within the past four weeks. This ensures that the treatment team has current information about the size and extent of the cancer when the trial begins. Repeat biopsies may sometimes be needed if the original diagnostic tissue is not adequate for the trial’s requirements or if significant time has passed since the initial diagnosis.

Molecular testing has become increasingly important for clinical trial qualification, even in squamous cell carcinoma. While this cancer type has fewer targetable genetic mutations compared to adenocarcinoma, some trials may require testing for specific genetic changes or biomarkers (measurable indicators of disease) that could predict response to experimental treatments. These tests examine the DNA of cancer cells to look for specific mutations or alterations that might make the tumor more or less likely to respond to certain therapies.

Clinical trials also typically require assessment of your overall health status and organ function. This includes blood tests to check kidney and liver function, blood cell counts, and other laboratory values. These tests help ensure that you are healthy enough to tolerate the experimental treatment and that your organs are functioning well enough to process the medications safely. Heart function tests, such as electrocardiograms or echocardiograms, may be required for trials involving drugs that could affect the heart.

Performance status assessment is another standard component of clinical trial eligibility. This evaluation measures how well you can perform daily activities and how much the cancer is affecting your physical functioning. Doctors often use standardized scales to rate performance status, and many trials have minimum requirements to ensure participants can safely undergo the treatment being studied.

Documentation of previous treatments is essential for clinical trial enrollment. If you have already received treatment for your squamous cell carcinoma, the trial coordinators will need detailed records of what therapies you received, when you received them, and how your cancer responded. Some trials are designed specifically for patients who have never received treatment, while others focus on patients whose cancer has not responded to standard therapies or has returned after initial treatment.